3 Dividend Stocks to Watch as Earnings Season Heats Up
Tomorrow, long-standing dividend companies will announce their earnings. Ahead of the earnings, Colgate-Palmolive stock is undergoing a consolidation Meanwhile, Proctor & Gamble stock...
-
-
Let's Grab A Coffee China
Market ScorecardWell, Mr. Market seems to have a very short attention span these days. Stock prices fell yesterday, reversing the previous session's gains as traders focused on comments from...
-
Oil’s Iran Cliffhanger: What To Know And What To Expect
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking for 'win'...
-
3 Healthcare Giants Bucking The Bear Market
Healthcare stocks have been some of this year’s best performers Defensive, blue-chips with reasonable valuations and strong dividends tend to do well in a bear market Consider buying...
-
3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
Fed's expected aggressive tightening to contain soaring inflation, has many worrying about a possible recession. Three companies to protect your portfolio due to strong fundamentals,...
-
2 ETFs For Betting On A Rebound In European Stocks
Concerns over high inflation levels and the war in Ukraine have meant increased volatility for stocks on Wall Street and other exchanges around the world. For instance, the DAX index of...
-
Novavax Bulls: Benefit From Cash-Secured Puts On The Biotech's Beaten-Down Stock
Pre-commercial biotech group Novavax’s stock is down more than 45% in January. The FDA has not yet authorized Novavax’s vaccine for use in the US. Long-term investors could...
-
3 Trades On Eli Lilly Stock As Pharma Investors Await Q4 Results
LLY, one of the best-performing pharma stocks in 2021, was down over 6% in the first week of the new year. Wall Street concurs that innovation across its core therapeutic areas has meant...
-
2 ETFs To Support New Year's Investing Resolutions
January 2022 could be a good time to review financial goals and start investing regularly. Long-term investors know that time is always on their side.Here’s why: Let’s assume you are now 30...
-
2021 Year In Review: Investing.com Comic Edition
Compiled by Jesse CohenWith just one trading day left this year, Wall Street’s major indices are on track to close 2021 at record highs as optimism over the global economy appears to have...
-
3 Year-To-Date Winners Set For More Highs As Omicron Fears Jolt Markets
Global financial markets are being whipsawed this week. Stocks on Wall Street have been suffering one of their worst selloffs of the year, as concerns over the spread of the Omicron...
-
2 ETFs That Could See Better Days In December
The final week of November brought increased volatility to broader markets. But when looking at the year as a whole, so far the Dow Jones, the S&P 500 and the NASDAQ 100 are up 12.9%,...
-
Pfizer Q1 Earnings Preview: Vaccine Sales In Focus As Stock Fails To Impress
Reports Q1 results on Tuesday, May 4, before the market open Revenue Expectation: $13.67 billion EPS Expectation: $0.78 Despite developing the first authorized COVID-19 vaccine to be used...
-
After AstraZeneca, Oxford Nanopore Might Be The Next UK COVID Winner
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University; BioNTech (NASDAQ:BNTX) / Pfizer (NYSE:PFE);...
-
Chart Of The Day: Moderna Outlook Improves After J&J Vaccine Pause
Yesterday, the US Food and Drug Administration halted the use of Johnson & Johnson's (NYSE:JNJ) one-shot coronavirus vaccine when a rare blood-clotting disorder developed in six women...
-
U.S. Dollar: Vaccine Concerns Overshadow CPI
The biggest news on Tuesday turned out to be concerns about the Johnson & Johnson (NYSE:JNJ) vaccine and not the U.S. inflation report. The country’s two health agencies (FDA and CDC)...
-
Chart Of The Day: Fundamentals And Technicals Agree, Pfizer Is Heading Higher
The Director General of the World Health Organization, Tedros Adhanom Ghebreyesus, warned on Monday that the pandemic is “a long way from over,” due to confusion and complacency....
-
4 Reasons For Big Moves In Currencies This Week
It will be another busy week for the financial markets, with potentially big moves in currencies and equities. On Wednesday, U.S. President Joe Biden will outline his $3-trillion...
-
Time to Buy Euros? Not Yet
One of the best performing currencies today was the euro. After selling off quickly and aggressively in the first week of March from a high of 1.21 to a low of 1.1835, the single currency...
-
For U.S. Dollar, Fed Action Speaks Louder Than Words
Actions speak louder than words for U.S. dollar traders who sent the greenback sharply higher after the Federal Reserve said the temporary change to the supplementary leverage ratio, or SLR,...
-
Oil Selloff: The Volatility Is Probably Just Beginning
Oil bears think a barrel of US crude will hit the low $50 levels next, and UK Brent under $60, to extend this week’s selloff.I think instead that oil’s one-way trade over the past...
-
Cocoa, Chocolate Demand Could Melt On Europe Vaccine Crisis
Nearly 3,000 miles from the Zurich headquarters of Barry Callebaut (SIX:BARN), Ghana’s cocoa traders are anxiously watching how the Swiss chocolatier will respond to the controversy that's...
-
Treasury Yields Rise As Uncertain Europe Outlook Pressures Sovereign Bonds
Yields on the benchmark 10-year Treasury note remained above 1.6% on Monday ahead of the Federal Reserve policy meeting Tuesday and Wednesday, as more analysts look for the pivotal yield to...
-
FX Outlook: Biggest Risks From FOMC, Retail Sales And BoE
This will be a busy week for the forex market. There are three central bank meetings, U.S. retail sales, New Zealand Q4 GDP, Australia’s employment report and Canadian retail sales scheduled...
-
Chart Of The Day: Moderna Set For Explosive Move (But Not Yet Clear Which Way)
Saying that Moderna (NASDAQ:MRNA) was the best performing COVID-19 vaccine stock in the past year would be a laughable understatement. Shares of AstraZeneca (NASDAQ:AZN) gained 0.25% for...
-
Chart Of The Day: What's The Deal With Bearish AstraZeneca Technicals?
If UK regulators approved the use of AstraZeneca's (NASDAQ:AZN) COVID-19 vaccine on Dec. 30, and began administering it this past Monday—becoming the first country in the world to do so—why...
-
2 ETFs For Investors With Financial New Year's Resolutions
Wall Street had a stellar comeback since the lows of spring 2020. The Dow Jones Industrial Average, the S&P 500 index, and the NASDAQ 100 index ended the year up by 7.2%, 16.3%, and...
-
December 2020 Market Wrap: Modest Gains After A Huge Year. What's Next?
For pure drama this past year, it was hard to beat the performances of global financial markets. Except possibly via the U.S. presidential election and its aftermath.December 2020 produced...
-
2 Multifactor ETFs To Boost Diversification Via A Single Fund
Looking to diversify across asset classes, investment styles, or regions? Multifactor exchange-traded funds are worth considering.There are around 300 multifactor exchange-traded funds...
-
COVID-19 Vaccine: Does It Make Sense To Buy Moderna After Its 600% Jump?
Buying shares of the companies that are developing vaccines against COVID-19 has been a great bet this year. Some of the leading candidates in the race to beat the deadly virus have seen...
-
3 Stocks Likely To Benefit From A Vaccine-Enabled Return To Normalcy
Positive news on COVID-19 vaccine progress has sparked a massive rally on Wall Street this month, with both the Dow Jones Industrial Average and S&P 500 notching a series of new record highs...
-
Georgia's Special Election Will Determine U.S. Energy Policy And World Prices
This article was written exclusively for Investing.comCrude oil returns to $40 per barrel pivot point; XLE makes a comeback Natural gas tumbles going into peak demand season Runoff election...
-
October Market Wrap: Downward Slide Shows Investors Are Hungry For Clarity
The stock market generally moves up or down based on investor expectations about the future. October's market performance, during which the major indices endured their worst weekly losses...
-
September Wrap: After Modest Stock Pullback, Buckle Up For A Jittery October
When August ended, stocks looked poised to move higher. The Federal Reserve {{art-200535780||had promised to keep interest rates at record low levels, effectively telling investors and...
-
With Oil Shares Like BP Cheap, Is A Contrarian Bet A Good Move In October?
The year 2020 has not been kind to the oil industry. Brent crude, the international benchmark, started the year around $60. By late April, it was below $20. When various lockdowns eased in...
-
Chart Of The Day: AstraZeneca's Fundamentals, Technicals Continue To Diverge
The strongest and fastest equity market rally in decades, which occurred from the March 2020 lows till mid-September of this year, was fueled by two complementary fundamental themes: the...
-
Could AstraZeneca Shares Be On The Way To New Highs?
The COVID-19 pandemic has created several equity market winners, including pharma giant AstraZeneca (LON:AZN) (NYSE:AZN). The company, along with its partner Oxford University, is developing...
-
Commodities Week Ahead: Gold On Fed Watch; Oil Tracks Sally, Pre-OPEC+
The Federal Reserve holds the keys this week to the dollar and, by its extension, gold. Geopolitics have also reared their head the first time in months to give the safe-haven a boost after...
-
As The USD Stumbles, Now Could Be A Good Time To Buy European ETFs
The recent decline in the US Dollar Index against other major currencies has made many market participants wonder: is now a good time to invest in European stocks?The greenback lost around...
-
Silver Prices Charge Higher, Markets Boosted By Positive News
The Lone Ranger galloped into town upon Silver and the precious metals markets are seeing fireworks this morning, following plenty yesterday. Silver prices are {{art-200531333||exploding...
-
FX: Vaccine and Stimulus Talk Sparks Optimism
This new trading week kicked off with broad-based gains for currencies. Every major currency pair, from EUR/USD to USD/JPY, moved higher as vaccine progress and stimulus talk sparked...
-
In The Search For A COVID Cure, Biopharma ETFs May Keep Your Portfolio Healthy
Over the past several months healthcare has become a top priority for individuals and governments alike around the globe. Many now regard a potential drug, or a vaccine, as a fast-track to a...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
